Willow Biosciences (TSE: WLLW- OTCQX: CANSF) CEO Trevor Peters joined Steve Darling from Proactive to shares news the company has announced details of a series of studies with development partner, Signum Biosciences, that demonstrate the safety and anti-inflammatory, anti-ageing, and antimicrobial properties of their cannabigerol.
Peters telling Proactive the company, being able to demonstrate the safety and benefit of a new ingredient like Willow's CBG, is a very critical step in commercialization. Peters says they plan on presenting the findings at the upcoming Society for Investigative Dermatology meeting in May.